NOVARTIS

Sponsor

Novartis Pharmaceuticals

Generic Drug Name

HDM201, MBG453, Venetoclax

Trial Indication(s)

Acute myeloid leukemia (AML) Or myelodysplastic syndrome (MDS)

Protocol Number

CHDM201H12101C

Protocol Title

A phase Ib, multi-arm, open-label, study of HDM201 in combination with MBG453 or venetoclax in adult subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)

Clinical Trial Phase

Phase 1b

Phase of Drug Development

Phase Ib

Study Start/End Dates

Study Start Date: June 24, 2019 (Actual)

Primary Completion Date: August 20, 2024 (Actual)
Study Completion Date: August 20, 2024 (Actual)

Reason for Termination (If applicable)

Business decision

Study Design/Methodology

This was a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 (Treatment arm 1) or venetoclax (Treatment arm 2) in patients with AML or high-risk MDS.

A dose-escalation approach was undertaken to determine the recommended dose of HDM201 in combination with MBG453 or with venetoclax. The HDM201 starting dose was 20 mg via oral administration once daily on Day 1-5 of a 28-day cycle for both combination treatments. In Treatment arm 1, the starting dose and regimen for MBG453 (via i.v. infusion) was 400 mg Q2W and subsequently dose and regimen of 800 mg Q4W was administered. In Treatment arm 2, venetoclax dose was gradually increased (ramp-up) over a period of 4 days to achieve the target daily dose tested of 400 mg.

Cohorts of 3 to 6 evaluable patients were planned to be enrolled in the dose escalation part including at least six patients at each maximum tolerated dose (MTD) (if achieved) and at each of the selected recommended dose (RD). At least 18 patients were expected to be treated in each arm, for the dose escalation model to have robust operating characteristics relating to its MTD/RD recommendation. It was anticipated that a total of approximately 80 patients would be enrolled in the study. The following cohorts were finally created:

Arm 1	Arm 2
• HDM201 20mg + MBG453 400mg • HDM201 40mg + MBG453 400mg • HDM201 40mg + MBG453 800mg • HDM201 60mg + MBG453 800mg	• HDM201 20mg + Venetoclax 400mg • HDM201 30mg + Venetoclax 400mg • HDM201 40mg + Venetoclax 400mg

Enrollment was halted in treatment arm 1 as of 17-Nov-2021, due to limited clinical benefit. The small sample sizes per dosing regimen impacted on the MTD evaluation. Treatment arm 2 was halted as of 17-Nov-2022, due to business decision. For both treatment arms enrollment was not completed as planned. The decision of enrollment halt for both arms was not a consequence of any safety concern.

Centers

9 centers in 7 countries: Australia(1), Finland(1), Singapore(1), Spain(1), Italy(2), United States(1), Germany(2)

Objectives:

Primary objective:

To characterize safety and tolerability of HDM201+MBG453 (Treatment arm 1) and HDM201+venetoclax (Treatment arm 2) and identify recommended doses and regimens for future studies. The endpoints for this objective include incidence and severity of AEs and SAEs, (including changes in laboratory values, vital signs, and ECGs), incidence and nature of dose limiting toxicities (DLTs), and dose interruptions, reductions, and dose intensity.

The secondary objectives are:

- To characterize the pharmacokinetic (PK) profile of investigational drugs (HDM201, MBG453 and venetoclax) administered in combination. The endpoints include PK parameters and concentration vs. time profiles
- To assess emergence of anti-MBG453 antibodies following one or more i.v. infusions of MBG453 in combination with HDM201 (Treatment arm 1 only). The endpoints include the presence and/or concentration of anti-MBG453 antibodies
- To evaluate preliminary anti-tumor activity of each treatment arm. The endpoints include overall response rate (ORR), best overall response (BOR) event-free survival (EFS), relapse-free survival (RFS) and duration of response (DOR) for patients with AML; ORR, BOR, progression free survival (PFS), time to relapse (TTR) and DOR for patients with MDS
- To assess the pharmacodynamics (PD) effect of each treatment arm. The endpoints include the changes from baseline in GDF-15 (Treatment arms 1 & 2), and the changes from baseline in soluble TIM-3 (Treatment arm 1 only).

Test Product (s), Dose(s), and Mode(s) of Administration

HDM201 was administered orally (p.o.) in a fasted state at least 1 hour before or 2 hours after a meal on day 1-5 of a 28-day cycle, with a starting dose at 20 mg.

MBG453 was administered via i.v. infusion over 30 minutes (up to 2 hours if clinically indicated), with dose at 400 mg once every 2 weeks (Q2W) or 800 mg once every 4 weeks (Q4W).

Venetoclax was administered orally (p,o.) with a 4--day ramp-up to the targeted dose of 400 mg once a day (QD) according to the local label instructions.

Statistical Methods

The endpoints for the primary objective to characterize safety and tolerability of HDM201 in combination with MBG453 or with venetoclax included: incidence and severity of AEs, SAEs, and abnormal values in clinical laboratory evaluation, ECGs, vital signs and physical exams, incidence of DLT for dose escalation, dose interruptions, reductions, and dose intensity.

A Bayesian Hierarchical Logistic Regression Model (BHLRM) guided by the EWOC principle were applied for the DLT analyses for dose-escalation decisions. Tolerability of study drug treatment was assessed by summarizing the number and percentage of dose interruptions and dose reductions per patient. Dose intensity and relative dose intensity of HDM201, as well as MBG453 and venetoclax per patient were also summarized. Adverse events were summarized by treatment arms (Treatment arm 1 and Treatment arm 2), for all patients by treatment groups (different combination doses).

Study Population: Key Inclusion/Exclusion Criteria

Main Inclusion Criteria:

• Male or female patients ≥ 18 years of age at the date of ICF signature who present with one of the following:

1. Relapsed/refractory AML following ≥1 prior therapies (but ≤3 prior therapies) who have relapsed or exhibited refractory disease (primary failure) and are deemed by the Investigator not to be candidates for standard therapy, including re-induction with cytarabine or other established chemotherapy regimens for patients with AML (patients who are suitable for standard re-induction chemotherapy

or hematopoietic stem cell transplantation and willing to receive it are excluded)

2. First line AML patient unfit for standard induction chemotherapy (includes both de novo and secondary AML), except in countries where approved therapies are available. Patients who are suitable for hematopoietic stem cell transplantation and willing to receive it are excluded.

3. High-risk MDS patient (high and very high-risk groups according to rIPSS) who have failed hypomethylating agent therapy.

• ECOG performance status ≤ 1

• TP53wt tumor. At minimum exons 5, 6, 7 and 8 in the TP53 gene must be sequenced and determined to contain no mutations. The TP53 status must be obtained from a bone-marrow sample, collected no longer than 3 months before signing the main ICF.

• Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to the institutional guidelines and be willing to undergo a bone marrow aspirate and/or biopsy at screening, during and at the end of therapy on this study. Exceptions may be considered after documented discussion with Novartis.

Main Exclusion Criteria:

Patients eligible for this study must not meet any of the following criteria:

• Prior combination treatment with compounds having the same mode of action:

o mdm2 or mdm4 inhibitors combined with TIM-3 inhibitors (for patients enrolled in treatment arm1)

o mdm2 or mdm4 inhibitors combined with Bcl-2 inhibitor (for patients enrolled in treatment arm2)

• History of severe hypersensitivity reactions to any ingredient of study drug(s) and other monoclonal antibodies (mAbs) and/or their excipients.

• Patients with acute promyelocytic leukemia with PML-RARA.

• Allogeneic stem cell transplant (HSCT) within last 6 months and/or active GvHD requiring systemic immunosuppressive therapy.

• GI disorders impacting absorption of oral HDM201 or venetoclax.

• Evidence of active bleeding or bleeding diathesis or major coagulopathy (including familial).

• Patients with active, known or suspected autoimmune disease (treatment arm 1 only).

Participant Flow Table

Overall Study

	HDM201 20mg + MBG453 400mg	HDM201 40mg + MBG453 400mg	HDM201 40mg + MBG453 800mg	HDM201 60mg + MBG453 800mg	HDM201 20mg + Venetoclax 400mg	HDM201 30mg + Venetoclax 400mg	HDM201 40mg + Venetoclax 400mg	Total
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	
Started	4	5	4	4	11	18	6	52
Completed	0	0	0	0	0	1	0	1
Not Completed	4	5	4	4	11	17	6	51
Death	1	2	0	0	2	1	1	7
Progressive disease	2	2	3	4	7	11	1	30
Subject decision	0	1	1	0	0	0	0	2
Adverse Event	1	0	0	0	2	3	4	10
Physician Decision	0	0	0	0	0	2	0	2

NOVARTIS

Baseline Characteristics

	HDM201 20mg + MBG453 400mg	HDM201 40mg + MBG453 400mg	HDM201 40mg + MBG453 800mg	HDM201 60mg + MBG453 800mg	HDM201 20mg + Venetoclax 400mg	HDM201 30mg + Venetoclax 400mg	HDM201 40mg + Venetoclax 400mg	Total
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD-4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD-4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD-4 day RU)	
Number of Participants [units: participants]	4	5	4	4	11	18	6	52
Baseline Analysis Population Description								
Age, Customized (units: Participants) Analysis Population Type: Participants Count of Participants (Not Applicable)								
In utero	0	0	0	0	0	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0	0	0	0	0	0
Newborns (0-27 days)	0	0	0	0	0	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0	0	0	0	0	0
Children (2-11 years)	0	0	0	0	0	0	0	0
Adolescents (12-17 years)	0	0	0	0	0	0	0	0
Adults (18-64 years)	1	0	0	2	4	6	1	14
From 65-84 years	3	5	4	2	7	12	5	38
85 years and over	0	0	0	0	0	0	0	0

Sex: Female, Male
(units: Participants)
Analysis Population Type: Participants
Count of Participants (Not Applicable)

Female	2	2	0	1	5	9	5	24
Male	2	3	4	3	6	9	1	28

Race (NIH/OMB)
(units: Participants)
Analysis Population Type: Participants
Count of Participants (Not Applicable)

American Indian or Alaska Native	0	0	0	0	0	0	0	0
Asian	1	0	1	0	2	2	0	6
Native Hawaiian or Other Pacific Islander	0	0	0	0	0	0	0	0
Black or African American	0	0	0	0	0	0	0	0
White	3	5	3	4	9	16	6	46
More than one race	0	0	0	0	0	0	0	0
Unknown or Not Reported	0	0	0	0	0	0	0	0

Study Specific Characteristic
Disease classification at study entry
(units: participants)
Description: The diagnosis of acute myeloid leukemia (AML) adhered to World Health Organization (WHO) definition of AML adopted by the IWG, i.e. ≥ 20% of the nucleated cells in the bone marrow aspirate must be blast cells of myeloid origin. Diagnosis of myelodysplastic syndrome (MDS) was made according to the WHO definition. The revised International Prognostic Scoring System (rIPSS) was used for classifying patients with high and very high-risk MDS.
Analysis Population Type: Participants
Count of Participants (Not Applicable)

Secondary and R/R acute myeloid leukemia (AML)	3	4	3	4	10	17	3	44
High-risk myelodysplastic syndrome (MDS)	0	0	1	0	1	0	2	4
Very high-risk myelodysplastic syndrome (MDS)	1	1	0	0	0	1	1	4

NOVARTIS

Primary Outcome Result(s)

Number of participants with dose interruptions and dose reductions - HDM201

Description	Tolerability measured by the number of subjects who have interruptions or reductions of study treatment.
Time Frame	From first dose of study treatment until last dose up to approximately 0.7 years for HDM201+MBG453 and 3.8 years for HDM201+Venetoclax
Analysis Population Description	The Safety Set (SS) includes patients who received any study drug and had at least one valid post-baseline safety assessment.

	HDM201 20mg + MBG453 400mg	**HDM201 40mg + MBG453 400mg**	**HDM201 40mg + MBG453 800mg**	**HDM201 60mg + MBG453 800mg**	**HDM201 20mg + Venetoclax 400mg**	**HDM201 30mg + Venetoclax 400mg**	**HDM201 40mg + Venetoclax 400mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	4	5	4	4	11	18	6
Number of participants with dose interruptions and dose reductions - HDM201 (units: participants)	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**
HDM201-At least one dose reduction or interruption	3 (75%)	2 (40%)	2 (50%)	0 (%)	7 (63.64%)	11 (61.11%)	2 (33.33%)
HDM201- at least one dose reduction	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	1 (5.56%)	0 (%)

HDM201-at least one dose interruption	3 (75%)	2 (40%)	2 (50%)	0 (%)	7 (63.64%)	11 (61.11%)	2 (33.33%)

Number of participants with dose interruptions and dose reductions - MBG453 / HDM210+MBG453

Description	Tolerability measured by the number of subjects who have interruptions or reductions of study treatment.
Time Frame	From first dose of study treatment until last dose up to approximately 0.7 years
Analysis Population Description	The Safety Set (SS) includes patients who received any study drug and had at least one valid post-baseline safety assessment.

	HDM201 20mg + MBG453 400mg	**HDM201 40mg + MBG453 400mg**	**HDM201 40mg + MBG453 800mg**	**HDM201 60mg + MBG453 800mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W
Number of Participants Analyzed [units: participants]	4	5	4	4
Number of participants with dose interruptions and dose reductions - MBG453 / HDM210+MBG453 (units: Participants)	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**
MBG453-at least one dose reduction or interruption	1 (25%)	3 (60%)	2 (50%)	0 (%)
MBG453-at least one dose reduction	0 (%)	0 (%)	0 (%)	0 (%)
MBG453-at least one dose interruption	1 (25%)	3 (60%)	2 (50%)	0 (%)
HDM201+MBG453-at least a dose reduction/interrupt.	3 (75%)	3 (60%)	3 (75%)	0 (%)
HDM201+MBG453-at least one dose reduction	0 (%)	0 (%)	0 (%)	0 (%)

HDM201+MBG453-at least one dose interruption	3 (75%)	3 (60%)	3 (75%)	0 (%)

Number of participants with dose interruptions and dose reductions - Venetoclax / HDM201+Venetoclax

Description	Tolerability measured by the number of subjects who have interruptions or reductions of study treatment. No statistical analysis was planned for this primary outcome.
Time Frame	From first dose of study treatment until last dose up to approximately 3.8 years
Analysis Population Description	The Safety Set (SS) includes patients who received any study drug and had at least one valid post-baseline safety assessment.

	HDM201 20mg + Venetoclax 400mg	**HDM201 30mg + Venetoclax 400mg**	**HDM201 40mg + Venetoclax 400mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	11	18	6
Number of participants with dose interruptions and dose reductions - Venetoclax / HDM201+Venetoclax (units: Participants)	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**
Venetoclax-at least a dose reduction/interruption	8 (72.73%)	12 (66.67%)	3 (50%)
Venetoclax-at least one dose reduction	1 (9.09%)	2 (11.11%)	1 (16.67%)
Venetoclax- at least one dose interruption	8 (72.73%)	12 (66.67%)	3 (50%)
HDM201+Venetoclax-at least a dose reduct/interrupt	8 (72.73%)	13 (72.22%)	3 (50%)
HDM201 + Venetoclax-at least one dose reduction	1 (9.09%)	3 (16.67%)	1 (16.67%)

HDM201 + Venetoclax-at least one dose interruption	8 (72.73%)	13 (72.22%)	3 (50%)

Dose intensity - HDM201

Description	Tolerability was measured by the dose of study drug. Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of exposure.
Time Frame	From first dose of study treatment until last dose up to approximately 0.7 years for HDM201+MBG453 and 3.8 years for HDM201+Venetoclax
Analysis Population Description	The Safety Set (SS) includes patients who received any study drug and had at least one valid post-baseline safety assessment.

	HDM201 20mg + MBG453 400mg	**HDM201 40mg + MBG453 400mg**	**HDM201 40mg + MBG453 800mg**	**HDM201 60mg + MBG453 800mg**	**HDM201 20mg + Venetoclax 400mg**	**HDM201 30mg + Venetoclax 400mg**	**HDM201 40mg + Venetoclax 400mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	4	5	4	4	11	18	6
Dose intensity - HDM201 (units: mg/day)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
HDM201	20 ± 0	37.9 ± 3.5	39 ± 2	54.9 ± 7.3	18.7 ± 2.3	28.4 ± 3.5	42.7 ± 8.6

Dose intensity - MBG453

Description	Tolerability was measured by the dose of study drug. Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of exposure.

Time Frame	From first dose of study treatment until last dose up to approximately 0.7 years
Analysis Population Description	The Safety Set (SS) includes patients who received any study drug and had at least one valid post-baseline safety assessment.

	HDM201 20mg + MBG453 400mg	HDM201 40mg + MBG453 400mg	HDM201 40mg + MBG453 800mg	HDM201 60mg + MBG453 800mg
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W
Number of Participants Analyzed [units: participants]	4	5	4	4
Dose intensity - MBG453 (units: mg/day)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
	400 ± 0	366.7 ± 47.1	800 ± 0	800 ± 0

Dose intensity - venetoclax

Description	Tolerability was measured by the dose of study drug. Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of exposure.
Time Frame	From first dose of study treatment until last dose up to approximately 3.8 years
Analysis Population Description	The Safety Set (SS) includes patients who received any study drug and had at least one valid post-baseline safety assessment.

	HDM201 20mg + Venetoclax 400mg	HDM201 30mg + Venetoclax 400mg	HDM201 40mg + Venetoclax 400mg
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)

Number of Participants Analyzed [units: participants]	11	18	6
Dose intensity - venetoclax (units: mg/day)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
	330 ± 59	317 ± 78.5	318.3 ± 51.5

Number of participants with dose limiting toxicities

Description	A dose-limiting toxicity (DLT) is defined as an adverse event (AE) or abnormal laboratory value that occurs during the first cycle of treatment and meets any of the protocol specified criteria, unless incontrovertibly related to underlying disease, intercurrent illness or concomitant medications.
Time Frame	First cycle of treatment (28 days)
Analysis Population Description	The Safety Set (SS) includes patients who received any study drug and had at least one valid post-baseline safety assessment.

	HDM201 20mg + MBG453 400mg	**HDM201 40mg + MBG453 400mg**	**HDM201 40mg + MBG453 800mg**	**HDM201 60mg + MBG453 800mg**	**HDM201 20mg + Venetoclax 400mg**	**HDM201 30mg + Venetoclax 400mg**	**HDM201 40mg + Venetoclax 400mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	4	3	4	4	7	16	5
Number of participants with dose limiting toxicities (units: Participants)	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**

	0 (%)	0 (%)	0 (%)	0 (%)	1 (14.29%)	2 (12.5%)	0 (%)

Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety

Description	Incidence and severity of AEs and SAEs by treatment group including changes in laboratory values, vital signs, and electrocardiograms (ECGs) qualifying and reported as AEs.
Time Frame	From first dose of study treatment until 30 days after last dose up to approximately 0.8 years for HDM201+MBG453 and 3.9 years for HDM201+Venetoclax.
Analysis Population Description	The Safety Set (SS) includes patients who received any study drug and had at least one valid post-baseline safety assessment.

	HDM201 20mg + MBG453 400mg	**HDM201 40mg + MBG453 400mg**	**HDM201 40mg + MBG453 800mg**	**HDM201 60mg + MBG453 800mg**	**HDM201 20mg + Venetoclax 400mg**	**HDM201 30mg + Venetoclax 400mg**	**HDM201 40mg + Venetoclax 400mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	4	5	4	4	11	18	6
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety (units: Participants)	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**
Adverse events	4 (100%)	5 (100%)	4 (100%)	4 (100%)	11 (100%)	18 (100%)	6 (100%)
Treatment related AEs	3 (75%)	4 (80%)	4 (100%)	4 (100%)	9 (81.82%)	16 (88.89%)	6 (100%)

Serious adverse events	4 (100%)	5 (100%)	4 (100%)	4 (100%)	8 (72.73%)	14 (77.78%)	4 (66.67%)
Treatment related SAEs	1 (25%)	1 (20%)	3 (75%)	1 (25%)	3 (27.27%)	4 (22.22%)	3 (50%)
Fatal SAEs	1 (25%)	3 (60%)	1 (25%)	0 (%)	2 (18.18%)	1 (5.56%)	2 (33.33%)
AEs requiring additional therapy	4 (100%)	5 (100%)	4 (100%)	4 (100%)	10 (90.91%)	17 (94.44%)	6 (100%)

Secondary Outcome Result(s)

Best Overall Response (BOR) - AML

Description	The best overall disease response is the best disease response recorded from the start of the treatment until treatment failure/ relapse. Efficacy was based on standardized response criteria defined by the International Working Group (IWG) for AML (Cheson criteria 2003). Response evaluation was based on the Investigator's assessment.
Time Frame	From first dose of study treatment until last dose up to approximately 0.7 years for HDM201+MBG453 and 3.8 years for HDM201+Venetoclax Units: Participants Percentage:
Analysis Population Description	AML Participants in the Full analysis set (FAS) with an available value for the outcome measure. The FAS comprised all participants who received any study drug i.e. at least one dose of any component of the combination therapy (HDM201 or MBG453 or venetoclax).

	HDM201 20mg + MBG453 400mg	**HDM201 40mg + MBG453 400mg**	**HDM201 40mg + MBG453 800mg**	**HDM201 60mg + MBG453 800mg**	**HDM201 20mg + Venetoclax 400mg**	**HDM201 30mg + Venetoclax 400mg**	**HDM201 40mg + Venetoclax 400mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)

Number of Participants Analyzed [units: participants]	3	1	3	3	10	15	2
Best Overall Response (BOR) - AML (units: Participants)	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**
Complete Remission (CR)	0 (%)	0 (%)	0 (%)	0 (%)	1 (10%)	0 (%)	0 (%)
CR with incomplete blood count recovery (CRi)	0 (%)	0 (%)	0 (%)	0 (%)	2 (20%)	7 (46.67%)	0 (%)
Partial Remission (PR)	0 (%)	0 (%)	0 (%)	0 (%)	1 (10%)	1 (6.67%)	1 (50%)
Relapsed from CR, CRi or PR	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
Treatment Failure (TF)	3 (100%)	1 (100%)	3 (100%)	3 (100%)	4 (40%)	5 (33.33%)	1 (50%)
No response	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	2 (13.33%)	0 (%)
Unknown	0 (%)	0 (%)	0 (%)	0 (%)	2 (20%)	0 (%)	0 (%)

Best Overall Response (BOR) - MDS

Description	The overall response rate (ORR), defined as the proportion of subjects with best overall response (BOR) of complete response (CR) or partial response (PR). Efficacy was based on on standardized response criteria as proposed by the International Working Group (IWG) for MDS (Cheson criteria 2006). Response evaluation was based on the Investigator's assessment.
Time Frame	From first dose of study treatment until last dose up to approximately 0.7 years for HDM201+MBG453 and 3.8 years for HDM201+Venetoclax
Analysis Population Description	MDS Participants in the Full analysis set (FAS) with an available value for the outcome measure. The FAS comprised all participants who received any study drug i.e. at least one dose of any component of the combination therapy (HDM201 or MBG453 or venetoclax).

	HDM201 20mg + MBG453 400mg	HDM201 40mg + MBG453 400mg	HDM201 40mg + MBG453 800mg	HDM201 20mg + Venetoclax 400mg	HDM201 30mg + Venetoclax 400mg	HDM201 40mg + Venetoclax 400mg
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	0	1	0	1	1	3
Best Overall Response (BOR) - MDS (units: Participants)	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**
Complete Response (CR)	(NaN%)	0 (%)	(NaN%)	1 (100%)	0 (%)	0 (%)
Bone marrow CR	(NaN%)	0 (%)	(NaN%)	0 (%)	0 (%)	0 (%)
Partial Response (PR)	(NaN%)	0 (%)	(NaN%)	0 (%)	0 (%)	0 (%)
Stable Disease (SD)	(NaN%)	0 (%)	(NaN%)	0 (%)	0 (%)	0 (%)
Relapse after CR or PR	(NaN%)	0 (%)	(NaN%)	0 (%)	0 (%)	0 (%)
Disease Progression (PD)	(NaN%)	1 (100%)	(NaN%)	0 (%)	1 (100%)	1 (33.33%)
Cytogenetic response	(NaN%)	0 (%)	(NaN%)	0 (%)	0 (%)	0 (%)
Unknown	(NaN%)	0 (%)	(NaN%)	0 (%)	0 (%)	2 (66.67%)

Overall Response Rate (ORR) - AML

Description: The overall response rate (ORR), defined as the proportion of subjects with best overall response (BOR) of complete response (CR) or partial response (PR). Efficacy was based on standardized response criteria defined by the International Working Group (IWG) for AML (Cheson criteria 2003). Response evaluation was based on the Investigator's assessment.

Time Frame: From first dose of study treatment until last dose up to approximately 0.7 years for HDM201+MBG453 and 3.8 years for HDM201+Venetoclax

Analysis Population Description: AML Participants in the Full analysis set (FAS) with an available value for the outcome measure. The FAS comprised all participants who received any study drug i.e. at least one dose of any component of the combination therapy (HDM201 or MBG453 or venetoclax).

	HDM201 20mg + MBG453 400mg	**HDM201 40mg + MBG453 400mg**	**HDM201 40mg + MBG453 800mg**	**HDM201 60mg + MBG453 800mg**	**HDM201 20mg + Venetoclax 400mg**	**HDM201 30mg + Venetoclax 400mg**	**HDM201 40mg + Venetoclax 400mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	3	1	3	3	10	15	2
Overall Response Rate (ORR) - AML (units: percentage of participants)	**Number (95% Confidence Interval)**	**Number (95% Confidence Interval)**	**Number (95% Confidence Interval)**	**Number (95% Confidence Interval)**	**Number (95% Confidence Interval)**	**Number (95% Confidence Interval)**	**Number (95% Confidence Interval)**
	0 (0 to 70.8)	0 (0 to 97.5)	0 (0 to 70.8)	0 (0 to 70.8)	40.0 (12.2 to 73.8)	47.1 (26.6 to 78.7)	33.3 (1.3 to 98.7)

Overall Response Rate (ORR) - MDS

Description: The overall response rate (ORR), defined as the proportion of subjects with best overall response (BOR) of complete response (CR) or partial response (PR). Efficacy was based on on standardized response criteria as proposed by the International Working Group (IWG) for MDS (Cheson criteria 2006). Response evaluation was based on the Investigator's assessment.

Time Frame	From first dose of study treatment until last dose up to approximately 0.7 years for HDM201+MBG453 and 3.8 years for HDM201+Venetoclax
Analysis Population Description	MDS Participants in the Full analysis set (FAS) with an available value for the outcome measure. The FAS comprised all participants who received any study drug i.e. at least one dose of any component of the combination therapy (HDM201 or MBG453 or venetoclax).

	HDM201 20mg + MBG453 400mg	HDM201 40mg + MBG453 400mg	HDM201 40mg + MBG453 800mg	HDM201 20mg + Venetoclax 400mg	HDM201 30mg + Venetoclax 400mg	HDM201 40mg + Venetoclax 400mg
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	0	1	0	1	1	3
Overall Response Rate (ORR) - MDS (units: percentage of participants)	**Number (95% Confidence Interval)**	**Number (95% Confidence Interval)**	**Number (95% Confidence Interval)**	**Number (95% Confidence Interval)**	**Number (95% Confidence Interval)**	**Number (95% Confidence Interval)**
		0 (0 to 97.5)		100 (2.5 to 100)	0 (0 to 97.5)	0 (0 to 70.8)

Event Free Survival (EFS) - AML

Description	Event-free survival (EFS) is the time from date of randomization/ start of treatment to the date of death from any cause, treatment failure or relapse. In case of treatment failure, the event date will be set to the date of randomization/ start of treatment. EFS was to be estimated using the Kaplan-Meier method.
Time Frame	From first dose of study treatment to date of death, treatment failure or relapse, up to approximately 3.9 years
Analysis Population Description	AML Participants in the Full analysis set (FAS) with an available value for the outcome measure. The FAS comprised all participants who received any study drug i.e. at least one dose of any component of the combination therapy (HDM201 or MBG453 or venetoclax).

	HDM201 20mg + MBG453 400mg	HDM201 40mg + MBG453 400mg	HDM201 40mg + MBG453 800mg	HDM201 60mg + MBG453 800mg	HDM201 20mg + Venetoclax 400mg	HDM201 30mg + Venetoclax 400mg	HDM201 40mg + Venetoclax 400mg
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	3	3	3	4	10	13	3
Event Free Survival (EFS) - AML (units: Months)	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**
	0.0 (0.0 to NA)[1]	1.2 (0.0 to NA)[1]	1.9 (0.0 to NA)[1]	3.6 (1.2 to NA)[1]	3.3 (0.0 to 8.2)	3.6 (0.0 to 5.5)	0.8 (0.0 to NA)[1]

[1] NA: Not estimable due to insufficient number of participants with events

Relapse Free Survival (RFS) - AML

Description	Relapse-free survival is measured by the time from achievement of complete response (CR), morphologic CR with incomplete blood count recovery (CRi) or parcial response (PR) whatever occurs first to relapse or death due to any cause during CR, CRi or PR. RFS was to be estimated using the Kaplan-Meier method.
Time Frame	From first time of CR/CRi/PR to date of death, treatment failure or relapse, up to approximately 3.9 years.
Analysis Population Description	AML Participants in the Full analysis set (FAS) with an available value for the outcome measure. The FAS comprised all participants who received any study drug i.e. at least one dose of any component of the combination therapy (HDM201 or MBG453 or venetoclax).

	HDM201 20mg + MBG453 400mg	HDM201 40mg + MBG453 400mg	HDM201 40mg + MBG453 800mg	HDM201 60mg + MBG453 800mg	HDM201 20mg + Venetoclax 400mg	HDM201 30mg + Venetoclax 400mg	HDM201 40mg + Venetoclax 400mg
Arm/Group Description	HDM201 20mg (Day 1-5, 28	HDM201 40mg (Day 1-5, 28	HDM201 40mg (Day 1-5, 28	HDM201 60mg (Day 1-5, 28	HDM201 20mg (Day 1-5, 28	HDM201 30mg (Day 1-5, 28	HDM201 40mg (Day 1-5, 28

	day cycle) + MBG453 400mg Q2W	day cycle) + MBG453 400mg Q2W	day cycle) + MBG453 800mg Q4W	day cycle) + MBG453 800mg Q4W	day cycle) + Venetoclax 400mg (QD- 4 day RU)	day cycle) + Venetoclax 400mg (QD- 4 day RU)	day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	0	0	0	0	3	3	1
Relapse Free Survival (RFS) - AML (units: Months)	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**
					6.4 (2.9 to NA)[1]	3.8 (2.3 to NA)[1]	0.8 (NA to NA)[1]

[1] NA: Not estimable due to insufficient number of participants with events

Duration of Remission (DOR) - AML

Description	DOR is defined as the duration from the first documented onset of PR, CRi or CR to the date of relapse or death due to AML. Efficacy was based on standardized response criteria defined by the International Working Group (IWG) for AML (Cheson criteria 2003). Response evaluation was based on the Investigator's assessment. DOR was to be estimated using the Kaplan-Meier method.
Time Frame	From first time of CR/CRi/PR to date of death, treatment failure or relapse, up to approximately 3.9 years.
Analysis Population Description	AML Participants in the Full analysis set (FAS) with an available value for the outcome measure. The FAS comprised all participants who received any study drug i.e. at least one dose of any component of the combination therapy (HDM201 or MBG453 or venetoclax).

	HDM201 20mg + MBG453 400mg	**HDM201 40mg + MBG453 400mg**	**HDM201 40mg + MBG453 800mg**	**HDM201 60mg + MBG453 800mg**	**HDM201 20mg + Venetoclax 400mg**	**HDM201 30mg + Venetoclax 400mg**	**HDM201 40mg + Venetoclax 400mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)

Number of Participants Analyzed [units: participants]	0	0	0	0	1	2	1
Duration of Remission (DOR) - AML (units: Months)	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**
					7.1 (NA to NA)[1]	NA (2.3 to NA)[1]	0.8 (NA to NA)[1]

[1] NA: Not estimable due to insufficient number of participants with events

progression free survival (PFS) - MDS

Description	Progression-free survival (PFS) is defined as time from date of randomization/start of treatment to date of death due to any cause or PD/relapse. PFS was estimated using the Kaplan-Meier method.
Time Frame	From first dose of study treatment to date of death, treatment failure or relapse, up to approximately 3.9 years.
Analysis Population Description	MDS Participants in the Full analysis set (FAS) with an available value for the outcome measure. The FAS comprised all participants who received any study drug i.e. at least one dose of any component of the combination therapy (HDM201 or MBG453 or venetoclax).

	HDM201 20mg + MBG453 400mg	**HDM201 40mg + MBG453 400mg**	**HDM201 40mg + MBG453 800mg**	**HDM201 20mg + Venetoclax 400mg**	**HDM201 30mg + Venetoclax 400mg**	**HDM201 40mg + Venetoclax 400mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	1	1	1	1	1	1
progression free survival (PFS) - MDS (units: Months)	**Median (95%**	**Median (95%**	**Median (95%**	**Median (95%**	**Median (95%**	**Median (95%**

	Confidence Interval)	Confidence Interval)	Confidence Interval)	Confidence Interval)	Confidence Interval)	Confidence Interval)
	NA (NA to NA)[1]	1.9 (NA to NA)[1]	NA (NA to NA)[1]	10.5 (NA to NA)[1]	0.9 (NA to NA)[1]	2.8 (1.5 to NA)[1]

[1] NA: Not estimable due to insufficient number of participants with events

Time to Relapse (TTR) - MDS

Description	Time to relapse is defined as the time between date of first documented CR and/or PR to the date of first documented relapse or death due to any cause, whichever occurs first. TTR was estimated using the Kaplan-Meier method.
Time Frame	From first time of CR/CRi/PR to date of death, or relapse due to any cause, up to approximately 3.9 years.
Analysis Population Description	MDS Participants in the Full analysis set (FAS) with an available value for the outcome measure. The FAS comprised all participants who received any study drug i.e. at least one dose of any component of the combination therapy (HDM201 or MBG453 or venetoclax).

	HDM201 20mg + MBG453 400mg	HDM201 40mg + MBG453 400mg	HDM201 40mg + MBG453 800mg	HDM201 60mg + MBG453 800mg	HDM201 20mg + Venetoclax 400mg	HDM201 30mg + Venetoclax 400mg	HDM201 40mg + Venetoclax 400mg
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	0	0	0	0	1	1	3
Time to Relapse (TTR) - MDS (units: Months)	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**
					8.7 (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]

[1] NA: Not estimable due to insufficient number of participants with events

Duration of Response (DOR) - MDS

Description	Duration of response (DOR) is defined as the duration from the first documented onset of PR or better response to the date of PD/relapse or death due to MDS. MDS was to be estimated using the Kaplan-Meier method.
Time Frame	From first time of CR/CRi/PR to date of death, treatment failure or relapse, up to approximately 3.9 years.
Analysis Population Description	MDS Participants in the Full analysis set (FAS) with an available value for the outcome measure. The FAS comprised all participants who received any study drug i.e. at least one dose of any component of the combination therapy (HDM201 or MBG453 or venetoclax).

	HDM201 20mg + MBG453 400mg	**HDM201 40mg + MBG453 400mg**	**HDM201 40mg + MBG453 800mg**	**HDM201 60mg + MBG453 800mg**	**HDM201 20mg + Venetoclax 400mg**	**HDM201 30mg + Venetoclax 400mg**	**HDM201 40mg + Venetoclax 400mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	0	0	0	0	1	1	3
Duration of Response (DOR) - MDS (units: Months)	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**	**Median (95% Confidence Interval)**
					NA (NA to NA)[1]	NA (NA to NA)[1]	NA (NA to NA)[1]

[1] NA: Not estimable due to insufficient number of participants with events

PK parameter (AUClast) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)

Description	The area under the concentration-time curve (AUC) of HDM201 from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1) based on plasma concentrations of HDM2
Time Frame	Cycle 1: Pre-dose, 0.5, 1, 2, 3, 4, 8, 24 hours post-dose on Day1. Pre-dose, 1, 2, 3, 4, 8, 24 hours post-dose on Day 5. One cycle = 28 days
Analysis Population Description	The Pharmacokinetic analysis set (PAS) includes all patients who provide an evaluable PK profile.

	HDM201 20mg + MBG453 400mg	**HDM201 40mg + MBG453**	**HDM201 60mg + MBG453 800mg**	**HDM201 20mg + Venetoclax 400mg**	**HDM201 30mg + Venetoclax 400mg**	**HDM201 40mg + Venetoclax 400mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg + MBG453 400mg Q2W and HDM201 40mg + MBG453 800mg Q4W were combined together.	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	4	8	4	11	18	6
PK parameter (AUClast) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) (units: hours*ng/mL)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
Cycle 1 Day 1	4540 ± 4150	4930 ± 1870	6500 ± 2530	2940 ± 1390	4090 ± 1320	5890 ± 2090
Cycle 1 Day 5	4460 ± 3160	7200 ± 3140	8710 ± 2930	4250 ± 2150	4570 ± 1840	9540 ± 5210

PK parameter (AUCtau) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)

Description	The area under the concentration-time curve (AUC) of HDM201 calculated to the end of a dosing interval (tau) (mass × time × volume-1) based on plasma concentrations of HDM201
Time Frame	Cycle 1: Pre-dose, 0.5, 1, 2, 3, 4, 8, 24 hours post-dose on Day1. Pre-dose, 1, 2, 3, 4, 8, 24 hours post-dose on Day 5. One cycle = 28 days
Analysis Population Description	The Pharmacokinetic analysis set (PAS) includes all patients who provide an evaluable PK profile.

	HDM201 20mg + MBG453 400mg	**HDM201 40mg + MBG453**	**HDM201 60mg + MBG453 800mg**	**HDM201 20mg + Venetoclax 400mg**	**HDM201 30mg + Venetoclax 400mg**	**HDM201 40mg + Venetoclax 400mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg + MBG453 400mg Q2W and HDM201 40mg + MBG453 800mg Q4W were combined together.	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	4	8	4	11	18	6
PK parameter (AUCtau) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) (units: hours*ng/mL)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
Cycle 1 Day 1	4610 ± 4110	4930 ± 1870	7020 ± 3160	2890 ± 1370	4070 ± 1410	5860 ± 2020
Cycle 1 Day 5	4440 ± 3150	7200 ± 3140	8660 ± 2880	4250 ± 2250	4980 ± 1420	8960 ± 6290

PK parameter (Cmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)

Description	The maximum (peak) observed plasma drug concentration after single dose administration (mass × volume-1) based on plasma concentrations of HDM201.
Time Frame	Cycle 1: Pre-dose, 0.5, 1, 2, 3, 4, 8, 24 hours post-dose on Day1. Pre-dose, 1, 2, 3, 4, 8, 24 hours post-dose on Day 5. One cycle = 28 days
Analysis Population Description	The Pharmacokinetic analysis set (PAS) includes all patients who provide an evaluable PK profile.

	HDM201 20mg + MBG453 400mg	**HDM201 40mg + MBG453**	**HDM201 60mg + MBG453 800mg**	**HDM201 20mg + Venetoclax 400mg**	**HDM201 30mg + Venetoclax 400mg**	**HDM201 40mg + Venetoclax 400mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg + MBG453 400mg Q2W and HDM201 40mg + MBG453 800mg Q4W were combined together.	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	4	8	4	11	18	6
PK parameter (Cmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) (units: ng/mL)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
Cycle 1 Day 1	312 ± 233	368 ± 96.8	432 ± 152	217 ± 113	305 ± 87.4	438 ± 142
Cycle 1 Day 5	310 ± 152	471 ± 148	594 ± 110	296 ± 162	337 ± 108	629 ± 256

NOVARTIS

PK parameter (Tmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)

Description	The time to reach maximum (peak) plasma drug concentration after single dose administration (time) based on plasma concentrations of HDM201.
Time Frame	Cycle 1: Pre-dose, 0.5, 1, 2, 3, 4, 8 hours post-dose on Day1. Pre-dose, 1, 2, 3, 4, 8 hours post-dose on Day 5. Pre-dose on day 2 and 6. One cycle = 28 days
Analysis Population Description	The Pharmacokinetic analysis set (PAS) includes all patients who provide an evaluable PK profile.

	HDM201 20mg + MBG453 400mg	**HDM201 40mg + MBG453**	**HDM201 60mg + MBG453 800mg**	**HDM201 20mg + Venetoclax 400mg**	**HDM201 30mg + Venetoclax 400mg**	**HDM201 40mg + Venetoclax 400mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg + MBG453 400mg Q2W and HDM201 40mg + MBG453 800mg Q4W were combined together.	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	4	8	4	11	18	6
PK parameter (Tmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) (units: Hours)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
Cycle 1 Day 1	2.99 ± 0.857	5.74 ± 6.38	3.57 ± 3.01	2.33 ± 0.958	5.20 ± 6.85	2.35 ± 0.579
Cycle 1 Day 5	2.85 ± 0.592	3.38 ± 2.07	2.74 ± 0.850	4.36 ± 6.50	3.20 ± 2.03	3.74 ± 3.42

PK parameter (AUClast) of MBG453 (treatment arm 1 HDM201+MBG453)

Description	The area under the concentration-time curve (AUC) of MBG453 from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1) based on serum concentrations of MBG453.
Time Frame	Q2W - Cycle 1 and 3: Pre-infusion, 1, 24, 168, 240 and 336 hours post end of infusion on Day 1. Q4W - Cycle 1 and 3: Pre-infusion, 1, 24,168, 240, 336 and 672 post end of infusion on Day 1. One cycle = 28 days
Analysis Population Description	The Pharmacokinetic analysis set (PAS) includes all patients who provide an evaluable PK profile.

	HDM201 + MBG453 400mg Q2W	**HDM201 + MBG453 800mg Q4W**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W and HDM201 40mg (Day 1-5, 28 day cycle) +MBG453 400mg Q2W were combined together.	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W and HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W were combined together.
Number of Participants Analyzed [units: participants]	8	8
PK parameter (AUClast) of MBG453 (treatment arm 1 HDM201+MBG453) (units: day*ug/mL)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
Cycle 1 Day 1	642 ± 207	1670 ± 591
Cycle 3 Day 1	980 ± 326	2510 ± 1360

PK parameter (AUCtau) of MBG453 (treatment arm 1 HDM201+MBG453)

Description	The area under the concentration-time curve (AUC) of HDM201 calculated to the end of a dosing interval (tau) (mass × time × volume-1) based on serum concentrations of MBG453
Time Frame	Q2W - Cycle 1 and 3: Pre-infusion, 1, 24, 168, 240 and 336 hours post end of infusion on Day 1. Q4W - Cycle 1 and 3: Pre-infusion, 1, 24,168, 240, 336 and 672 post end of infusion on Day 1. One cycle = 28 days
Analysis Population Description	The Pharmacokinetic analysis set (PAS) includes all patients who provide an evaluable PK profile.

	HDM201 + MBG453 400mg Q2W	HDM201 + MBG453 800mg Q4W
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W and HDM201 40mg (Day 1-5, 28 day cycle) +MBG453 400mg Q2W were combined together.	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W and HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W were combined together.
Number of Participants Analyzed [units: participants]	8	8
PK parameter (AUCtau) of MBG453 (treatment arm 1 HDM201+MBG453) (units: day*ug/mL)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
Cycle 1 Day 1	671 ± 214	1920 ± 373
Cycle 3 Day 1	984 ± 328	2670 ± 1130

PK parameter (Cmax) of MBG453 (treatment arm 1 HDM201+MBG453)

Description	The maximum (peak) observed plasma drug concentration after single dose administration (mass × volume-1) based on serum concentration of MBG453.
Time Frame	Q2W - Cycle 1 and 3: Pre-infusion, 1, 24, 168, 240 and 336 hours post end of infusion on Day 1. Q4W - Cycle 1 and 3: Pre-infusion, 1, 24,168, 240, 336 and 672 post end of infusion on Day 1. One cycle = 28 days
Analysis Population Description	The Pharmacokinetic analysis set (PAS) includes all patients who provide an evaluable PK profile.

	HDM201 + MBG453 400mg Q2W	HDM201 + MBG453 800mg Q4W
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W and HDM201 40mg (Day 1-5, 28 day cycle) +MBG453 400mg Q2W were combined together.	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W and HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W were combined together.

Number of Participants Analyzed [units: participants]	8	8
PK parameter (Cmax) of MBG453 (treatment arm 1 HDM201+MBG453) (units: ug/mL)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
Cycle 1 Day 1 n= 8,8	98.7 ± 24.4	175 ± 40.7
Cycle 3 Day 1 n= 4,3	138 ± 29.1	219 ± 17.6

PK parameter (Tmax) of MBG453 (treatment arm 1 HDM201+MBG453)

Description	The time to reach maximum (peak) plasma drug concentration after single dose administration (time) based on serum concentration of MBG453.
Time Frame	Q2W - Cycle 1 and 3: Pre-infusion, 1,24,168, 240 post infusion day 1. Pre-infusion and 1h post- infusion day 15. Q4W - Cycle 1 and 3: Pre-infusion, 1,24,168, 240, 360 post infusion day 1. One cycle = 28 days
Analysis Population Description	The Pharmacokinetic analysis set (PAS) includes all patients who provide an evaluable PK profile.

	HDM201 + MBG453 400mg Q2W	**HDM201 + MBG453 800mg Q4W**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W and HDM201 40mg (Day 1-5, 28 day cycle) +MBG453 400mg Q2W were combined together.	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W and HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W were combined together.
Number of Participants Analyzed [units: participants]	8	8
PK parameter (Tmax) of MBG453 (treatment arm 1 HDM201+MBG453) (units: Hours)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
Cycle 1 Day 1	0.883 ± 0.769	1.76 ± 0.374
Cycle 3 Day 1	1.43 ± 0.347	9.68 ± 14.0

NOVARTIS

PK parameter (AUClast) of venetoclax (treatment arm 2 HDM201+venetoclax)

Description	The area under the concentration-time curve (AUC) of venetoclax from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1) based on plasma concentrations of venetoclax.
Time Frame	Cycle 1: Pre-dose, 1, 2, 4, 8 and 24 hours post-dose on Day 1 and 5. One cycle = 28 days
Analysis Population Description	The Pharmacokinetic analysis set (PAS) includes all patients who provide an evaluable PK profile.

	HDM201 + Venetoclax 400mg
Arm/Group Description	HDM201 20mg + Venetoclax 400mg, HDM201 30mg + Venetoclax 400mg and HDM201 40mg + Venetoclax 400mg were combined together
Number of Participants Analyzed [units: participants]	34
PK parameter (AUClast) of venetoclax (treatment arm 2 HDM201+venetoclax) (units: Hours*ng/mL)	**Mean ± Standard Deviation**
Cycle 1 Day 1	4410 ± 2600
Cycle 1 Day 5	23700 ± 14900

PK parameter (AUCtau) of venetoclax (treatment arm 2 HDM201+venetoclax)

Description	The area under the concentration-time curve (AUC) of venetoclax calculated to the end of a dosing interval (tau) (mass × time × volume-1) based on plasma concentrations of venetoclax.
Time Frame	Cycle 1: Pre-dose, 1, 2, 4, 8 and 24 hours post-dose on Day 1 and 5. One cycle = 28 days
Analysis Population Description	The Pharmacokinetic analysis set (PAS) includes all patients who provide an evaluable PK profile.

HDM201 + Venetoclax 400mg

Arm/Group Description	HDM201 20mg + Venetoclax 400mg, HDM201 30mg + Venetoclax 400mg and HDM201 40mg + Venetoclax 400mg were combined together
Number of Participants Analyzed [units: participants]	11
PK parameter (AUCtau) of venetoclax (treatment arm 2 HDM201+venetoclax) (units: Hours*ng/mL)	**Mean ± Standard Deviation**
Cycle 1 Day 1	3650 ± 1500
Cycle 1 Day 5	22200 ± 14700

PK parameter (Cmax) of venetoclax (treatment arm 2 HDM201+venetoclax)

Description	The maximum (peak) observed plasma drug concentration after single dose administration (mass × volume-1) based on plasma concentrations of venetoclax.
Time Frame	Cycle 1: Pre-dose, 1, 2, 4, 8 and 24 hours post-dose on Day 1 and 5. One cycle = 28 days
Analysis Population Description	The Pharmacokinetic analysis set (PAS) includes all patients who provide an evaluable PK profile.

	HDM201 + Venetoclax 400mg
Arm/Group Description	HDM201 20mg + Venetoclax 400mg, HDM201 30mg + Venetoclax 400mg and HDM201 40mg + Venetoclax 400mg were combined together
Number of Participants Analyzed [units: participants]	34
PK parameter (Cmax) of venetoclax (treatment arm 2 HDM201+venetoclax) (units: ng/mL)	**Mean ± Standard Deviation**
Cycle 1 Day 1	332 ± 188
Cycle 1 Day 5	1610 ± 957

PK parameter (Tmax) of venetoclax (treatment arm 2 HDM201+venetoclax)

Description	The time to reach maximum (peak) plasma drug concentration after single dose administration (time) based on plasma concentrations of venetoclax.
Time Frame	Cycle 1: Pre-dose, 1, 2, 4, 8 and 24 hours post-dose on Day 1 and 5. One cycle = 28 days
Analysis Population Description	The Pharmacokinetic analysis set (PAS) includes all patients who provide an evaluable PK profile.

	HDM201 + Venetoclax 400mg
Arm/Group Description	HDM201 20mg + Venetoclax 400mg, HDM201 30mg + Venetoclax 400mg and HDM201 40mg + Venetoclax 400mg were combined together
Number of Participants Analyzed [units: participants]	34
PK parameter (Tmax) of venetoclax (treatment arm 2 HDM201+venetoclax) (units: Hours)	**Mean ± Standard Deviation**
Cycle 1 Day 1	6.11 ± 2.61
Cycle 1 Day 5	6.67 ± 3.24

Changes from baseline in GDF-15 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)

Description	Target engagement of HDM210 was measured through Growth differentiation Factor-15 protein levels in plasma pre and post-dose.
Time Frame	Pre-dose cycle 1 day 1 and post-dose cycle 1 day 2
Analysis Population Description	Participants in the Full analysis set (FAS) with an available value for the outcome measure. The FAS comprised all participants who received any study drug i.e. at least one dose of any component of the combination therapy (HDM201 or MBG453 or venetoclax).

	HDM201 20mg + MBG453 400mg	HDM201 40mg + MBG453	HDM201 60mg + MBG453 800mg	HDM201 20mg + Venetoclax 400mg	HDM201 30mg + Venetoclax 400mg	HDM201 40mg + Venetoclax 400mg
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg + MBG453 400mg Q2W and HDM201 40mg + MBG453 800mg Q4W were combined together.	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	4	7	4	11	17	6
Changes from baseline in GDF-15 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) (units: Fold change)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
	3.5 ± 0.35	6.0 ± 2.0	7.8 ± 4.0	5.1 ± 1.5	6.4 ± 2.3	7.3 ± 3.6

Changes from baseline in soluble TIM-3 (Treatment arm 1 HDM201+MBG453)

Description	Target engagement of MBG453 was measured through soluble T-cell Immunoglobulin domain and Mucin domain-3 (sTIM-3) levels in serum pre and post-dose.
Time Frame	Pre-dose cycle 1 day 1 and post-dose cycle 1 day 2
Analysis Population Description	Participants in the Full analysis set (FAS) with an available value for the outcome measure. The FAS comprised all participants who received any study drug i.e. at least one dose of any component of the combination therapy (HDM201 or MBG453 or venetoclax).

	HDM201 + MBG453 400mg Q2W	HDM201 + MBG453 800mg Q4W
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W and HDM201	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W and HDM201

	40mg (Day 1-5, 28 day cycle) +MBG453 400mg Q2W were combined together.	60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W were combined together.
Number of Participants Analyzed [units: participants]	7	8
Changes from baseline in soluble TIM-3 (Treatment arm 1 HDM201+MBG453) (units: Fold change)	**Mean ± Standard Deviation**	**Mean ± Standard Deviation**
	2.8 ± 1.4	3.8 ± 1.3

Presence of anti-MBG453 antibodies (treatment arm 1 HD201+MBG453)

Description	Number of subjects with anti-MBG453 antibodies (Anti-Drug Antibodies)
Time Frame	From baseline until last dose of study treatment up to approximately 3.8 years
Analysis Population Description	Participants in the Immunogenicity Incidence Set (IGIS) included all patients in the IGPS with a determinant baseline IG sample and at least one determinant post-baseline IG sample, who received MBG453 treatment. The Immunogenicity Prevalence Set (IGPS) includes all patients in the FAS with a determinant baseline IG sample or at least one determinant post-baseline IG sample, who received MBG453 treatment.

	HDM201 20mg + MBG453 400mg	**HDM201 40mg + MBG453 400mg**	**HDM201 40mg + MBG453 800mg**	**HDM201 60mg + MBG453 800mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W
Number of Participants Analyzed [units: participants]	3	3	3	3
Presence of anti-MBG453 antibodies (treatment arm 1 HD201+MBG453) (units: Participants)	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**
ADA-positive at baseline	0 (%)	1 (33.33%)	0 (%)	1 (33.33%)
ADA- positive after treatment	1 (33.33%)	0 (%)	0 (%)	1 (33.33%)

Other Pre-Specified Outcome Result(s)

No data identified.

Post-Hoc Outcome Result(s)

All collected deaths

Description	On-treatment deaths were collected from first dose of study treatment to 30 days after last dose. Post treatment and disease progression FU deaths were collected from 31 days after last dose until end of study. All deaths refer to the sum of pre-treatment deaths, on-treatment, post-treatment safety FU deaths, and disease progression FU deaths.
Time Frame	On-treatment deaths: up to approximately 0.8 years for HDM201+MBG453 and 3.9 years for HDM201+venetoclax. Post-treatment safety FU and disease progression FU deaths: up to 3.9 years
Analysis Population Description	The Safety Set (SS) includes patients who received any study drug and had at least one valid post-baseline safety assessment.

	HDM201 20mg + MBG453 400mg	**HDM201 40mg + MBG453 400mg**	**HDM201 40mg + MBG453 800mg**	**HDM201 60mg + MBG453 800mg**	**HDM201 20mg + Venetoclax 400mg**	**HDM201 30mg + Venetoclax 400mg**	**HDM201 40mg + Venetoclax 400mg**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Number of Participants Analyzed [units: participants]	4	5	4	4	11	18	6
All collected deaths (units: participants)	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**	**Count of Participants (Not Applicable)**

On-treatment deaths	1 (25%)	2 (40%)	1 (25%)	3 (75%)	3 (27.27%)	2 (11.11%)	4 (66.67%)
Post-treatment / disease progression FU deaths	2 (50%)	1 (20%)	2 (50%)	1 (25%)	2 (18.18%)	5 (27.78%)	1 (16.67%)
All deaths	3 (75%)	3 (60%)	3 (75%)	4 (100%)	4 (36.36%)	7 (38.89%)	5 (83.33%)

Safety Results

Time Frame	Adverse events: from first dose of study treatment until 150 days after last treatment up to maximum duration of 4.2 years Deaths: from first dose of study treatment until 150 days after last treatment up to maximum duration of 4.2 years
Source Vocabulary for Table Default	MedDRA 27.0
Collection Approach for Table Default	Systematic Assessment

All-Cause Mortality

	HDM201 20mg + MBG453 400mg N = 4	**HDM201 40mg + MBG453 400mg N = 5**	**HDM201 40mg + MBG453 800mg N = 4**	**HDM201 60mg + MBG453 800mg N = 4**	**HDM201 20mg + Venetoclax 400mg N = 11**	**HDM201 30mg + Venetoclax 400mg N = 18**	**HDM201 40mg + Venetoclax 400mg N = 6**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax

					400mg (QD-4 day RU)	400mg (QD-4 day RU)	400mg (QD- 4 day RU)
Total Number Affected	3	3	3	4	3	2	4
Total Number At Risk	4	5	4	4	11	18	6

Serious Adverse Events

Time Frame	Adverse events: from first dose of study treatment until 150 days after last treatment up to maximum duration of 4.2 years Deaths: from first dose of study treatment until 150 days after last treatment up to maximum duration of 4.2 years
Source Vocabulary for Table Default	MedDRA 27.0
Collection Approach for Table Default	Systematic Assessment

	HDM201 20mg + MBG453 400mg N = 4	**HDM201 40mg + MBG453 400mg N = 5**	**HDM201 40mg + MBG453 800mg N = 4**	**HDM201 60mg + MBG453 800mg N = 4**	**HDM201 20mg + Venetoclax 400mg N = 11**	**HDM201 30mg + Venetoclax 400mg N = 18**	**HDM201 40mg + Venetoclax 400mg N = 6**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD-4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD-4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Total # Affected by any Serious Adverse Event	4	5	4	4	8	14	4
Total # at Risk by any Serious Adverse Event	4	5	4	4	11	18	6

Blood and lymphatic system disorders							
Anaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	1 (5.56%)	0 (0.00%)
Bone marrow failure	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Febrile neutropenia	1 (25.00%)	1 (20.00%)	1 (25.00%)	2 (50.00%)	5 (45.45%)	8 (44.44%)	1 (16.67%)
Leukocytosis	0 (0.00%)	0 (0.00%)	2 (50.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Thrombocytopenia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	1 (5.56%)	0 (0.00%)
Cardiac disorders							
Acute coronary syndrome	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Angina pectoris	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Arteriosclerosis coronary artery	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Cardiac amyloidosis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Cardiac failure congestive	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Eye disorders							
Retinal haemorrhage	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Gastrointestinal disorders							
Diarrhoea	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	2 (18.18%)	0 (0.00%)	0 (0.00%)
Gastrointestinal haemorrhage	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Large intestinal obstruction	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Lower gastrointestinal haemorrhage	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Mouth ulceration	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Nausea	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Oesophagitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Pancreatitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Stomatitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Vomiting	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
General disorders and administration site conditions							
Chest pain	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Fatigue	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
General physical health deterioration	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Oedema peripheral	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Pyrexia	0 (0.00%)	1 (20.00%)	3 (75.00%)	0 (0.00%)	2 (18.18%)	0 (0.00%)	0 (0.00%)
Immune system disorders							
Graft versus host disease in skin	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Infections and infestations							
Anal abscess	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bacteraemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Bacterial sepsis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Clostridium difficile infection	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Corynebacterium bacteraemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
COVID-19	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Diverticulitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Infection	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Klebsiella sepsis	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Lower respiratory tract infection fungal	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Neutropenic sepsis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Oral candidiasis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Perinephric abscess	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Pharyngitis	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Pneumonia	0 (0.00%)	2 (40.00%)	1 (25.00%)	1 (25.00%)	1 (9.09%)	2 (11.11%)	0 (0.00%)
Sepsis	2 (50.00%)	1 (20.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (33.33%)
Septic shock	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Staphylococcal bacteraemia	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Staphylococcal sepsis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Urinary tract infection	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Vulvovaginitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Wound infection	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Injury, poisoning and procedural complications							
Transfusion reaction	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Investigations							
Blood creatinine increased	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Hepatic enzyme increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Metabolism and nutrition disorders							
Hypocalcaemia	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hypomagnesaemia	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Tumour lysis syndrome	0 (0.00%)	0 (0.00%)	1 (25.00%)	1 (25.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)

Musculoskeletal and connective tissue disorders							
Polymyalgia rheumatica	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)							
Acute myeloid leukaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Nervous system disorders							
Cerebrovascular accident	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Headache	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Transient ischaemic attack	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Renal and urinary disorders							
Haematuria	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Respiratory, thoracic and mediastinal disorders							
Dyspnoea	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Skin and subcutaneous tissue disorders							
Rash	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Vascular disorders							
Hypotension	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)

Other (Not Including Serious) Adverse Events

Time Frame	Adverse events: from first dose of study treatment until 150 days after last treatment up to maximum duration of 4.2 years Deaths: from first dose of study treatment until 150 days after last treatment up to maximum duration of 4.2 years
Source Vocabulary for Table Default	MedDRA 27.0
Collection Approach for Table Default	Systematic Assessment

Frequent Event Reporting Threshold 5%

	HDM201 20mg + MBG453 400mg N = 4	**HDM201 40mg + MBG453 400mg N = 5**	**HDM201 40mg + MBG453 800mg N = 4**	**HDM201 60mg + MBG453 800mg N = 4**	**HDM201 20mg + Venetoclax 400mg N = 11**	**HDM201 30mg + Venetoclax 400mg N = 18**	**HDM201 40mg + Venetoclax 400mg N = 6**
Arm/Group Description	HDM201 20mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 400mg Q2W	HDM201 40mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 60mg (Day 1-5, 28 day cycle) + MBG453 800mg Q4W	HDM201 20mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD-4 day RU)	HDM201 30mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD-4 day RU)	HDM201 40mg (Day 1-5, 28 day cycle) + Venetoclax 400mg (QD- 4 day RU)
Total # Affected by any Other Adverse Event	4	5	4	4	11	17	6
Total # at Risk by any Other Adverse Event	4	5	4	4	11	18	6
Blood and lymphatic system disorders							
Anaemia	3 (75.00%)	3 (60.00%)	2 (50.00%)	1 (25.00%)	3 (27.27%)	9 (50.00%)	2 (33.33%)
Coagulopathy	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	1 (5.56%)	0 (0.00%)
Febrile neutropenia	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (11.11%)	1 (16.67%)

Leukocytosis	1 (25.00%)	0 (0.00%)	2 (50.00%)	1 (25.00%)	1 (9.09%)	0 (0.00%)	1 (16.67%)
Leukopenia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (11.11%)	0 (0.00%)
Neutropenia	1 (25.00%)	1 (20.00%)	1 (25.00%)	2 (50.00%)	3 (27.27%)	6 (33.33%)	0 (0.00%)
Splenic infarction	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Thrombocytopenia	0 (0.00%)	1 (20.00%)	1 (25.00%)	3 (75.00%)	4 (36.36%)	5 (27.78%)	1 (16.67%)
Cardiac disorders							
Atrial fibrillation	1 (25.00%)	1 (20.00%)	0 (0.00%)	1 (25.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Bradycardia	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Cardiac failure congestive	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Palpitations	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Pericardial effusion	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (11.11%)	0 (0.00%)
Pericarditis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Sinus arrest	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Sinus tachycardia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Supraventricular tachycardia	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Tachycardia	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	1 (16.67%)
Ear and labyrinth disorders							
Vertigo	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Eye disorders							
Conjunctival haemorrhage	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Iritis	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Vision blurred	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Gastrointestinal disorders							

Abdominal discomfort	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Abdominal distension	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	1 (5.56%)	1 (16.67%)
Abdominal pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	2 (11.11%)	3 (50.00%)
Abdominal pain lower	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Abdominal pain upper	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	1 (16.67%)
Aphthous ulcer	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	1 (5.56%)	1 (16.67%)
Constipation	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (50.00%)	1 (9.09%)	2 (11.11%)	0 (0.00%)
Diarrhoea	0 (0.00%)	2 (40.00%)	2 (50.00%)	2 (50.00%)	5 (45.45%)	9 (50.00%)	4 (66.67%)
Dysphagia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Faeces soft	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Flatulence	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Gastritis haemorrhagic	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Gastrointestinal haemorrhage	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Gingival bleeding	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	3 (16.67%)	0 (0.00%)
Haematochezia	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Haemorrhoidal haemorrhage	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Haemorrhoids	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	2 (11.11%)	0 (0.00%)
Large intestinal obstruction	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Melaena	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Mouth haemorrhage	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Mouth ulceration	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Nausea	3 (75.00%)	1 (20.00%)	3 (75.00%)	3 (75.00%)	8 (72.73%)	10 (55.56%)	3 (50.00%)
Odynophagia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Oesophagitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Oral blood blister	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Oral disorder	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Oral mucosa haematoma	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Oral pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Proctalgia	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (11.11%)	0 (0.00%)
Proctitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Salivary gland pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Stomatitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (50.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Tooth disorder	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Vomiting	0 (0.00%)	1 (20.00%)	3 (75.00%)	1 (25.00%)	3 (27.27%)	4 (22.22%)	2 (33.33%)
General disorders and administration site conditions							
Asthenia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	2 (11.11%)	0 (0.00%)
Chest pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	1 (5.56%)	0 (0.00%)
Chills	1 (25.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Crepitations	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Discomfort	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Facial pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Fatigue	0 (0.00%)	1 (20.00%)	0 (0.00%)	1 (25.00%)	3 (27.27%)	3 (16.67%)	0 (0.00%)
Influenza like illness	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Localised oedema	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Malaise	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Mucosal inflammation	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Oedema	0 (0.00%)	1 (20.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Oedema peripheral	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	2 (18.18%)	3 (16.67%)	1 (16.67%)

Pain	0 (0.00%)	0 (0.00%)	1 (25.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Peripheral swelling	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	3 (16.67%)	0 (0.00%)
Physical deconditioning	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Pyrexia	0 (0.00%)	0 (0.00%)	2 (50.00%)	1 (25.00%)	3 (27.27%)	7 (38.89%)	3 (50.00%)
Hepatobiliary disorders							
Cholelithiasis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Cholestasis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Hyperbilirubinaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	1 (5.56%)	0 (0.00%)
Immune system disorders							
Graft versus host disease in skin	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Infections and infestations							
Alpha haemolytic streptococcal infection	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Anal abscess	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Bronchitis bacterial	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Candida infection	1 (25.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Clostridium difficile colitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Clostridium difficile infection	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Diverticulitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Endocarditis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Escherichia urinary tract infection	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Folliculitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Fungal infection	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	1 (5.56%)	0 (0.00%)

Herpes simplex reactivation	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Oral candidiasis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	3 (16.67%)	1 (16.67%)
Oral herpes	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Orchitis	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Oropharyngeal candidiasis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Parotitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Pharyngitis	1 (25.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Pneumonia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	2 (33.33%)
Pneumonia bacterial	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Rhinitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Septic shock	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Sinusitis bacterial	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Skin infection	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Staphylococcal bacteraemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Staphylococcal infection	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Suspected COVID-19	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Upper respiratory tract infection	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	1 (5.56%)	0 (0.00%)
Urinary tract infection	2 (50.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Injury, poisoning and procedural complications							
Contusion	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Ear injury	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Fall	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Infusion related reaction	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Limb injury	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Transfusion reaction	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	1 (5.56%)	0 (0.00%)
Investigations							
Alanine aminotransferase increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Amylase increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Aspartate aminotransferase increased	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Aspergillus test positive	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Bacterial test positive	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Blood albumin decreased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Blood bilirubin increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (18.18%)	1 (5.56%)	0 (0.00%)
Blood creatine phosphokinase increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Blood creatinine increased	0 (0.00%)	1 (20.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	2 (11.11%)	1 (16.67%)
Blood glucose increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Blood potassium increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Blood uric acid increased	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Cardiac murmur	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Chest X-ray abnormal	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
C-reactive protein increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (11.11%)	0 (0.00%)
Electrocardiogram QT prolonged	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Heart rate increased	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hepatic enzyme increased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Lipase increased	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	2 (18.18%)	0 (0.00%)	0 (0.00%)

Liver function test abnormal	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Lymphocyte count decreased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Neutrophil count decreased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (11.11%)	0 (0.00%)
Platelet count decreased	1 (25.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	2 (18.18%)	3 (16.67%)	0 (0.00%)
SARS-CoV-2 test negative	0 (0.00%)	1 (20.00%)	2 (50.00%)	0 (0.00%)	0 (0.00%)	3 (16.67%)	0 (0.00%)
SARS-CoV-2 test positive	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	2 (11.11%)	0 (0.00%)
Varicella virus test positive	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Weight decreased	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	3 (27.27%)	2 (11.11%)	0 (0.00%)
Weight increased	1 (25.00%)	0 (0.00%)	1 (25.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	2 (33.33%)
White blood cell count decreased	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
White blood cell count increased	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Metabolism and nutrition disorders							
Decreased appetite	0 (0.00%)	1 (20.00%)	1 (25.00%)	0 (0.00%)	2 (18.18%)	3 (16.67%)	1 (16.67%)
Electrolyte imbalance	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Gout	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Hypercalcaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Hyperglycaemia	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Hyperkalaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Hypernatraemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Hyperphosphataemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	1 (16.67%)
Hypervolaemia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	3 (16.67%)	3 (50.00%)
Hypoalbuminaemia	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)

Hypocalcaemia	0 (0.00%)	2 (40.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	1 (5.56%)	1 (16.67%)
Hypokalaemia	1 (25.00%)	2 (40.00%)	2 (50.00%)	0 (0.00%)	3 (27.27%)	4 (22.22%)	3 (50.00%)
Hypomagnesaemia	1 (25.00%)	2 (40.00%)	2 (50.00%)	1 (25.00%)	2 (18.18%)	3 (16.67%)	2 (33.33%)
Hyponatraemia	1 (25.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	1 (16.67%)
Hypophosphataemia	1 (25.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	1 (5.56%)	2 (33.33%)
Tumour lysis syndrome	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Musculoskeletal and connective tissue disorders							
Arthralgia	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Back pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	1 (5.56%)	0 (0.00%)
Bursitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Flank pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Haematoma muscle	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Muscular weakness	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Musculoskeletal chest pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Pain in extremity	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Polymyalgia rheumatica	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Sjogren's syndrome	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)							
Leukaemia cutis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Tumour flare	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Nervous system disorders							
Aphasia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Dizziness	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	2 (11.11%)	1 (16.67%)

Dysarthria	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Dysgeusia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	2 (11.11%)	0 (0.00%)
Dyskinesia	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Generalised tonic-clonic seizure	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Headache	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (18.18%)	3 (16.67%)	0 (0.00%)
Lethargy	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (11.11%)	0 (0.00%)
Paraesthesia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Somnolence	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Syncope	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Psychiatric disorders							
Confusional state	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Delirium	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Hallucination, visual	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Insomnia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	1 (5.56%)	0 (0.00%)
Mental status changes	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Nervousness	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Renal and urinary disorders							
Acute kidney injury	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Dysuria	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (16.67%)
Haematuria	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Pelvi-ureteric obstruction	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Pollakiuria	0 (0.00%)	1 (20.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Urinary incontinence	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	1 (16.67%)

Reproductive system and breast disorders							
Genital blister	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Respiratory, thoracic and mediastinal disorders							
Catarrh	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Cough	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	1 (16.67%)
Dry throat	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Dyspnoea	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Dyspnoea exertional	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (11.11%)	0 (0.00%)
Epistaxis	0 (0.00%)	0 (0.00%)	1 (25.00%)	1 (25.00%)	0 (0.00%)	3 (16.67%)	1 (16.67%)
Haemoptysis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (11.11%)	0 (0.00%)
Hypoxia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Pharyngeal disorder	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Pleural effusion	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	1 (16.67%)
Pneumonitis	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Pulmonary hilum mass	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Pulmonary mass	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	1 (9.09%)	1 (5.56%)	0 (0.00%)
Sinus pain	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Skin and subcutaneous tissue disorders							
Alopecia	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	1 (16.67%)
Cutaneous vasculitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Dry skin	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Erythema	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Night sweats	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	0 (0.00%)	0 (0.00%)
Petechiae	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	2 (11.11%)	0 (0.00%)

Pruritus	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	1 (5.56%)	1 (16.67%)
Rash	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Rash maculo-papular	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	1 (16.67%)
Skin lesion	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	1 (9.09%)	1 (5.56%)	0 (0.00%)
Skin necrosis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Skin ulcer	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Urticaria	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	2 (11.11%)	0 (0.00%)
Vascular disorders							
Deep vein thrombosis	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Haematoma	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	2 (11.11%)	1 (16.67%)
Hypertension	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (5.56%)	0 (0.00%)
Hypotension	0 (0.00%)	1 (20.00%)	0 (0.00%)	0 (0.00%)	2 (18.18%)	0 (0.00%)	0 (0.00%)
Phlebitis	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	2 (18.18%)	0 (0.00%)	0 (0.00%)
Thrombophlebitis	0 (0.00%)	0 (0.00%)	0 (0.00%)	1 (25.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

Other Relevant Findings

NA

Conclusion:

In this Phase 1b study exploring combinations of HDM201 with MBG453 or venetoclax in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS(, the results showed:

- The overall safety profile of both combination treatments was consistent with the known safety profiles of the individual treatments and there was no indication of additive or accumulated toxicities when administered in combination.
- Biomarker data demonstrated target engagement for both HDM201 and MBG453 in an overall dose-dependent manner.

- In Treatment arm 1, none of the patients showed a response to treatment and many patients did not reach the first response assessment due to progressive disease.
- In Treatment arm 2, 43.3% Overall Response Rate was observed in patients with R/R AML, with rates of complete response (CR) and Morphologic CR with incomplete blood count recovery (Cri) at 3.3% and 30%, respectively. Historically, when given as a single agent, venetoclax has demonstrated a combined CR/CRi rate of 19% in R/R AML. Definitive conclusions as to the benefit of adding HDM201 to venetoclax cannot be made due to the small sample size and inherent limitations of cross-trial comparisons.

Date of Clinical Trial Report

29 April 2025